FBXO44 inhibition reactivates REs, leading to IFNγ signaling activation in cancer cells, as shown by the increased expression of IFNGR1, IFNGR2, and other ISGs and the decreased expression of protein tyrosine phosphatase nonreceptor type 2 (PTPN2), an IFNγ signaling inhibitor [9]. Here, IFNGR1 is linked to cancer.